Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors

American Journal of Roentgenology

Volumn 202, Issue 2, 2014, Pages 406-412

  Paidpally, Vasavi ^a,b   Mercier, Gustavo ^a   Shah, Bhartesh A ^a   Senthamizhchelvan, Srinivasan ^b   Subramaniam, Rathan M ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

FDG PET CT; Metabolic tumor volume; Total lesion glycolysis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BREAST CANCER; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; FEMALE; GLYCOLYSIS; HEAD AND NECK CANCER; HUMAN; INTERREADER RELIABILITY; INTERREADER VARIABILITY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR; STATISTICAL PARAMETERS; TUMOR VOLUME;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84892733239     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.10841     Document Type: Article

References (27)

1. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med 2006; 47:901-903
2. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24:3282-3292
3. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50:122S-150S
4. Davison JM, Ozonoff A, Imsande HM, Grillone GA, Subramaniam RM. Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. Radiology 2010; 255:578-585
5. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. J Med Imaging Radiat Oncol 2009; 53:160-169; quiz, 170
6. 18FF FDG PET/CT imaging. J Thorac Oncol 2007; 2:569-570
7. Karantanis D, O'Neill BP, Subramaniam RM, et al. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. Clin Nucl Med 2007; 32:271-274
8. Jackson T, Chung MK, Mercier G, Ozonoff A, Subramaniam RM. FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. Nucl Med Commun 2012; 33:305-312
9. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors. Part 2. AJR 2011; 197:[web]W260-W265
10. Shum WY, Ding HJ, Liang JA, Yen KY, Chen SW, Kao CH. Use of pretreatment metabolic tumor volumes on PET-CT to predict the survival of patients with squamous cell carcinoma of esophagus treated by curative surgery. Anticancer Res 2012; 32:4163-4168
11. 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol 2013; 24:208-214
12. Abelson JA, Murphy JD, Trakul N, et al. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. Lung Cancer 2012; 78:219-224
13. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med 2012; 53:709-715
14. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med 2012; 53:1506-1513
15. Hatt M, Visvikis D, Le Rest CC. Autocontouring versus manual contouring. J Nucl Med 2011; 52:658; author reply, 658-659
16. Shah B, Srivastava N, Hirsch AE, Mercier G, Subramaniam RM. Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods. Ann Nucl Med 2012; 26:707-714
17. 18F-FDG PET-positive lymph nodes in radiotherapy of patients with nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 2007; 34:453-462
18. Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Gregoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol 2003; 69:247-250
19. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 1997; 80:2505-2509
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174
21. Hatt M, Cheze Le Rest C, Albarghach N, Pradier O, Visvikis D. PET functional volume delineation: a robustness and repeatability study. Eur J Nucl Med Mol Imaging 2011; 38:663-672
22. Dewalle-Vignion AS, Yeni N, Petyt G, et al. Evaluation of PET volume segmentation methods: comparisons with expert manual delineations. Nucl Med Commun 2012; 33:34-42
23. 18F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med 2011; 52:1690-1697
24. Paidpally V, Chirindel A, Lam S, Agrawal N, Quon H, Subramaniam RM. FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med 2012; 4:633-647
25. Romesser PB, Qureshi MM, Shah BA, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med 2012; 26:527-534
26. Davison J, Mercier G, Russo G, Subramaniam RM. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR 2013; 200:635-640
27. Bazan JG, Koong AC, Kapp DS, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med 2013; 54:27-32